Member Info for BuenaVista

Well Bella, I said 80 on 6 November but I just made it up with crayons and threw it out there to see whether it would flap around.

Predicting share prices and movements is a mugs game. If it does get to 80 next Thursday, what should I do? Sell and watch the price go up, never to see 80 ever again? Hold and have regrets whilst watching the price fall back to 70? Or hold and feel smug whilst watching the price move up to 90 but then have the same dilemma there? The share price can do what it wants but I won't be doing any trading, however small, unless the RSI clearly indicates vastly overbought or oversold and even then context is important.

Well said!!! HEMO definitely the best in class in this specific crowded cancer domain.

BeHEMOuth

I'm just euphoric to have graduated from Tesco to Waitrose.

No but I'm thrillled to share that I am about to

"Thrilled"... Remember, this is the nation where four year olds graduate from nursery and showing pleasure starts at overjoyed.

You also live in Liverpool

The Boston conference finished yesterday yet the IMC webinar isn't until Wednesday ...afternoon ...starting half an hour before the AIM market closes ...and noon, high noon, in Philly and NYC.... Why? Healthcare Royalty there. What deal are they organising?

/Bella

Avacta management talking with pharma majors post AACR. Deals incoming. Size buyers lining up, bagels and cawfee in hand, er hands. IPO next week. Full 10/- Nasdaq listing. GS advising Novartis. Terminate. Terminate. Terminate. 🤯

/HurstBot

It will always only be spikes on good clinical news until there is assured 🤑🤑🤑

Https://en.wikipedia.org/wiki/Biotechnology_industry_in_Boston

Biotechnology companies

Abcam

Addgene

Biogen

Boston Scientific

Conagen

Foundation Medicine

GSK

Genzyme

ImmunoGen

Intarcia Therapeutics

Moderna Therapeutics

NovoBiotic Pharmaceuticals

pSivida

Sage Therapeutics

Thrombolytic Science International

Thermo Fisher Scientific

Vaxess Technologies

Ventum Biotech

Waters Corporation

- - - - -

Pharmaceutical companies

AbbVie

Acceleron Pharma

Aderis Pharmaceuticals

Agios Pharmaceuticals

Akebia Therapeutics

Alkermes

Alnylam Pharmaceuticals

Alzheon

Amgen

Bayer

Bristol Myers Squibb

Editas Medicine

Eli Lilly and Company

Intellia Therapeutics

Ipsen

Ironwood Pharmaceuticals

Merck & Co.

Novartis

Novo Nordisk

Ono Pharmaceutical

Pfizer

Sanofi

Sarepta Therapeutics

Takeda Pharmaceuticals

Ultragenyx

Vertex Pharmaceuticals

Interesting that you feel compelled to 'defend' your investment. Smacks of uncertainty and insecurity.

Just spent an interesting half an hour asking for analysis of my character and personality and that of wyndrum, and for a straight comparison of the two. Never mind that it consumes the electrical power of a small nation, I've got a long list of others to do as well. Yes, it's a quiet time and, as aldebaran might say, I'm board.

Yeah, do us a favour and make it a triple marathon.

Haywain wrote: "I have researched both also - I just wonder at what point shareholders in Avacta will realise that the emperors lab coat is see through. This is the Hemo share chat we are not interested in doxorubicin thanks."

That is, literally, pure ignorance. You should absolutely avoid any involvement with Avacta.

That Avacta are developimg TWO lines of dual payload pre|CISION drugs when they don't have funds to carry faridox, let alone AVA6103, through the clinic strongly suggests that funding of one sort or another is coming ...er, shortly.

Look out for the blackcurrant-marmite combo flavour. Enormous health benefits but probably not going to be everyone's favourite.

Bella, that's the long way of saying "We have broad patent protection for this latest iteration of our core IP."

MMAE and the oldest PARPi are out of patent. As far as I can make out, the other PARPi's, including the by far the most potent one, and all ATRi's are still under patent. Whether Avacta is working with a big farmer on these is a moot point.

I prefer this version of the news release

I think these are fundamentally inferior to Avacta's dual warheads because they have two warheads attached to the antibody with no tumour-specific cleavable linker.

Written by AI, consumed by dimwits.😂💯👍👏🤷🏼‍♂️